Furthermore, study in both colon and breast cancer models shows that combination of immunotherapeutic stimulants with TNFR2-blocking antibodies not only inhibits the proliferation of cancer cells but also decreases the number of Tregs and the surface abundance of TNFR2 on Tregs, thus enhancing the effectiveness of treatment [103]. This evidence concerns the gene TNFRSF1B and breast carcinoma.